Finsbury Glover Hering and Sard Verbinnen & Co. Complete Merger, Creating Global Strategic Communications Leader
Following their announcement on October 13, 2021, Finsbury Glover Hering and Sard Verbinnen & Co. (“SVC”) have completed their merger to create the world’s leading strategic communications firm advising clients in navigating critical opportunities and challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005402/en/
The firm brings together over 1,000 communications professionals, operating from 25 offices in Asia, Europe, the Middle East and the United States, including its global headquarters in New York.
The new firm is a leader in all aspects of strategic communications, including government affairs, corporate reputation, crisis management and transformation and change, as well as the leading force in financial communications worldwide. Its professionals have deep sector knowledge within rapidly growing industries, such as Health, Tech, Food and Agriculture and Renewable Energy, as well as expertise in Diversity, Equity and Inclusion (DE&I), Environmental, Social and Governance (ESG), litigation and regulatory communications and cybersecurity.
Alexander Geiser, CEO, said: “We have created a true global partnership between two leaders in strategic communications that will allow us to meet the complex, rapidly changing needs of our clients. We are eager to get started and look forward to capitalizing on our depth of capabilities as one united firm.”
SVC Co-Founders George Sard and Paul Verbinnen added: “We are excited to bring together two firms with such complementary strengths and compatible cultures to create a new firm that will be far more than the sum of its parts. We have the expertise and experience to deliver reputation advisory services that address virtually all critical C-suite needs, with the scale to bring the right team to any situation, anywhere, at any time.”
Equity in the new company is owned by nearly 40 percent of the firm’s employees. WPP remains the majority investor. Golden Gate Capital, which was a significant minority investor in SVC, has converted its equity in SVC and remains an investor in the new firm.
The new firm will announce a new name and brand in early 2022.
It will serve its global client base from 25 offices in Abu Dhabi, Beijing, Berlin, Boston, Brussels, Chicago, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, Houston, London, Los Angeles, Munich, New York, Paris, Riyadh, San Francisco, Shanghai, Singapore, Tokyo, Washington D.C. and Zurich. A South Florida office will open shortly.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+44 7733 294 930
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BIOCORP Obtains 510(k) FDA Clearance for Mallya ®7.12.2022 07:30:00 CET | Press release
Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for BIOCORP and all of our employees who have been heavily involved in this regulatory process. This approval marks a historic achievement for BIOCORP as it allows the commercial launch of our Mallya device in the United States and illustrates BIOCORP's ability to meet the highest regulatory requirements. This news has been eagerly awaited by all our industry partners to commercialize Mallya in the world's largest diabetes market and we are delighted that U.S. patients will soon be able to benefit from Mallya's services. This regulatory milestone will have a positive
Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-109177.12.2022 07:11:00 CET | Press release
Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML). Be given to ODD, Delta-Fly Pharma, Inc. can be entitled to seven extra years of marketing exclusivity and receive some benefits such as R&D rebate by getting approval. DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed AML. A Phase 3 clinical study has been underway at MD Anderson Cancer Center in Texas and other major sites of Hematologic Cancer Treatment in USA. The company expects to complete the patients’ enrollment plan soon. Delta-Fly Pharma, Inc. focuses not only on cancer itself but on the whole conditions of cancer patients, and aims to deliver medicines that are recommendable for cancer patients and their families. Company profile Company name Delta-Fly Pharma, Inc. [Tokyo:4598] Capital 3352 million Japanese Ye
SLB Announces Pricing of Debt Tender Offer6.12.2022 22:05:00 CET | Press release
SLB (NYSE: SLB) today announced the consideration payable in connection with the previously announced offer (the “Offer”) by Schlumberger Holdings Corporation, an indirect wholly-owned subsidiary of SLB (“SHC”), to purchase for cash up to a certain amount of the notes listed in the table below (the “Notes”), pursuant to the terms and subject to the conditions set forth in the offer to purchase, dated November 21, 2022 (as may be amended or supplemented from time to time, the “Offer to Purchase”). Capitalized terms used but not defined in this press release have the meanings given to them in the Offer to Purchase. Title of Security CUSIP Numbers Acceptance Priority Level(1) Principal Amount Outstanding Principal Amount to be Purchased Early Tender Premium(1) Reference Security Bloomberg Reference Page Reference Yield Fixed Spread (basis points) Total Consideration (1)(2) 3.750% Senior Notes due 2024 806851AJ0 (144A) / U8066LAG9 (Reg S) 1 $750,000,000 $394,869,000 $30 2.500% U.S. Treasur
Media Alert: Prosimo to Exhibit at the Gartner® IOCS Conference 2022 and Present the Power of Single Architecture for Simplifying Multicloud Networking6.12.2022 17:24:00 CET | Press release
Prosimo, the Application Experience Infrastructure company, is demonstrating (Booth #511) its full-stack solution for simplifying multi-cloud networking at Gartner IT Infrastructure Operations & Cloud Strategies conference, taking place December 6-8th in Las Vegas. The company plans to present a customer case example of the advantages of using a single network infrastructure for its cloud computing services. The Gartner Market Guide for Multicloud Networking Software encourages I&O leaders responsible for cloud and edge infrastructure to “prefer the native capabilities of the cloud providers when starting out, and avoid forklifting data center networking designs and vendors in the public cloud, because this will lead to integration and cost inefficiencies.”1 And to “invest in MCNS when a consistent set of broader, “full-stack” Level 3 through Level 7 networking and network security capabilities (e.g., routing, DNS, CDN, WAF, firewall, and observability) via a single management platform
Fortius Metals Raises Seed Round of $2M from AM Ventures to Bring Advanced Metal 3D Printing to the Aerospace Industry6.12.2022 17:00:00 CET | Press release
Fortius Metals, Inc., an innovative metal 3D printing company, has announced today that it has closed on a priced seed financing round with AM Ventures. The $2M round will be used to scale manufacturing capacity, grow the company and accelerate its go-to-market strategy. Fortius Metals is a large format additive manufacturing company that specializes in advanced materials to help customers develop solutions previously not possible with robotic 3D printing. Fortius Metals’ patented technology will enable welding and 3D wire fabrication using high performance metal alloys to meet the exacting demands of aerospace customers and robotic welding fabricators. AM Ventures, the foremost venture capital firm for the additive manufacturing sector, focuses solely on startups built around industrial-grade 3D printing offerings, including hardware, software, materials, and applications. AM Ventures’ portfolio includes an elite group of 17 companies engaged in 3D printing, out of over 2,400 start-up
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom